Navarixin

Drug Profile

Navarixin

Alternative Names: MK-7123; PS-291822; SCH 527123; SCH 5271234

Latest Information Update: 29 May 2015

Price : $50

At a glance

  • Originator Pharmacopeia; Schering-Plough
  • Developer Ligand Pharmaceuticals; Merck & Co
  • Class Anti-inflammatories; Benzamides; Cyclobutanes
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 22 May 2013 Efficacy data from a phase II trial in Chronic obstructive pulmonary disease presented at the 109th International Conference of the American Thoracic Society (ATS-2013)
  • 01 Dec 2011 Merck terminates phase II trial in Chronic obstructive pulmonary disease in European Union, Russia, Ukraine, Australia, Canada, Mexico, Argentina, Chile, Peru and Venezuela (NCT01006616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top